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Evaluation of phenylpiperazines as targeting agents for neuroblastoma
JW Babich, WA Graham, AJ Fischman
Division ofNuclear Medicine ofthe Department ofRadiology, Massachusetts General Hospital and the Department ofRadiology,
Harvard Medical School, Boston, MA, USA.
Summary The potential of radiolabelled phenylpiperazines as agents for the detection and therapy of tumours
of neural crest origin was evaluated by in vitro pharmacological studies with human neuroblastoma cell lines
[SK-N-SH and SK-N-BE(2C)], and in vivo by biodistribution measurements. The ability of phenylpiperazines:
4-phenyl-piperazine (PP), 1-carboxamidino-4-phenyl-piperazine (CAPP), [4-(3-chlorophenyl)-piperazine
(mCPP), 4-(3-trifluoro methyl phenyl)-piperazine (TFMPP), and (1,1-dimethyl-4-phenyl)-piperazinium
hydrochloride (DMPP) and chlorophenyl hydroxypiperidine [CP(OH)P], to inhibit MIBG uptake by
neuroblastoma cells was determined by incubation with ['251]MIBG (0.1 pM) for 2 h in the presence of
varying concentrations (10-8_ 10-3 M) of ligand. For measuring uptake, cells were incubated with ['25I]IPP
(0.1 gM) and cell-associated radioactivity was measured at various times. Retention was studied by incubating
cells in the presence of [125I]IPP (0.1 jM) for 2 h, followed by replacement with drug-free medium and
determination of cell-bound radioactivity. Selectivity of[1251lIPP uptake was studied by inhibition studies with
MIBG, DMI, SHT and phenylpiperazines. The biodistribution of ['25I]IPP was measured in normal rats at
0.083, 0.5, 1, 2 and 24 h (six animals per group). The IC50s (gM) for inhibition of[125I]MIBG uptake were: PP,
1.5; CPP, 2.5; CAPP, 2.5; DMPP, 5; CP(OH)P, 30 and TFMPP, 65. The rate ofcellular uptake of[125]IPP was
greatest between 0 and 60 min and decreased after 60 min, similar to MIBG. After an initial rapid washout of
approximately 50% of the radioactivity, retention remained constant for 3 h. The IC50s (#M) for inhibition of
[125I]IPP uptake were: MIBG, 18-25; DMI, 0.6-1.5; 5HT, > 100; IPP, 1.8-2.5; CPP, 7.0-9.0 and TFMPP,
>,20. The in vivo studies demonstrated a pattern of distribution similar to MIBG. The results demonstrate that
phenylpiperazines display significant affinity for neuroblastoma with uptake and retention characteristics
similar to MIBG.
Keywords: neuroblastoma; phenylpiperazine; metaiodobenzylguanidine; targeted therapy
The radiopharmaceutical, meta-iodobenzylguanidine (MIBG)
has been shown to be sensitive and specific for the
scintigraphic detection of tumours of neural crest origin, in
particular, neuroblastoma (McEwan et al., 1985; Kimmig et
al., 1984; Hofnagel et al., 1985; Troncone et al., 1990).
Furthermore, the high degree of specific accumulation of
MIBG in this tumour has led to its use in therapy. Recent
reports (Lashford et al., 1992) have indicated that therapeutic
doses of [131I]MIBG induce remission in approximately 35%
of patients with relapses of pretreated disease. Although
encouraging results have been achieved in some patients, in
others there has been disappointment. Agents with improved
localising properties and pharmacokinetics would be useful.
The amine transporter system responsible for accumula-
tion of MIBG in the SK-N-BE(2C) neuroblastoma cell line
has less stringent substrate requirements than the transporters
on other neural cell types (Lashford et al., 1992). In addition,
it is well established that embryonic neural cells are capable
of differentiating into a variety of neuronal phenotypes
(Fraser and Bonner-Fraser 1991; Kentroti et al., 1994). Thus,
undifferentiated neuroblastomas may possess embryonic
amine transporters with high capacity but reduced selectivity
(i.e. the transporter is not yet committed to a particular
neurotransmitter). Hence, a variety of compounds may be
recognised and transported by the amine uptake system
expressed by neuroblastomas.
Owing to their ability to interact with a number of
neuronal receptor systems, the phenylpiperazines represent a
potentially interesting class of compounds for targeting
neuroblastoma (Pawowski, 1983; Abuzar and Sharma 1984;
Fuller, 1986; Glennon et al., 1991; Lloyd et al., 1985; Lyon et
al., 1986; Oepen et al., 1988). 4-(3-chlorophenyl)-piperazine
has been shown to be a serotonin agonist and several other
phenylpiperazine derivatives exhibit serotonin receptor
activity (Bagdy et al., 1989; Maj and Lewandowska, 1980).
The chlorine-containing phenylpiperazine, 4-(3-chlorophe-
nyl)-piperazine (mCPP) and the fluorinated derivative, 4-(3-
trifluoromethylphenyl)-piperazine (mTFMPP), both elicit a
dose-dependent release of serotonin from brain slices. This
effect is caused by displacement of serotonin stores and not
depolarisation (Pettibone and Williams, 1984). Since this
mechanism is similar to that described for the adrenergic
neuronal blocking agent, upon which MIBG was based, the
phenylpiperazine structure may offer a new basis for
developing neuroblastoma imaging agents. The observation
that mCPP inhibits serotonin and noradrenaline uptake in rat
synaptosomes to a similar degree (1.3 gM vs 5.8 guM
respectively) (Samanin et al., 1979) establishes that this
ligand interacts with the noradrenaline transporter.
Radioiodinated derivatives of phenylpiperazines have been
studied by several investigators. Hanson et al. (1985) have
described the biodistribution of several radioiodinated
phenylepiperazines including derivatives of 4-phenylpipera-
zine, the ganglionic-stimulating drug, 1,1-dimethyl-4-phenyl-
piperazinium (DMPP) (Hanson, 1982; Hanson et al., 1983),
1-carboxamidino-4-(['251]iodophenyl)piperazine (Hanson et
al., 1986) and 1-["C]methyl-4-aryl-piperazinium salts (Elma-
leh et al., 1993). These studies and others (Chumpradit et al.,
1989; Hanson and Hasan, 1987) have demonstrated that
phenylpiperazine derivatives accumulate in a variety of tissues
(brain, adrenal medulla and myocardium) to varying degrees.
These findings led to our investigation of the ability of
these ligands to compete for MIBG uptake in cultured
neuroblastoma. Initial results indicating that 1-carboxamidi-
no-4-phenylpiperazine (CAPP) inhibits MIBG uptake by SK-
N-BE(2C) cells prompted further investigations of this class
of compounds as second generation or alternative radio-
pharmaceuticals for targeting neuroblastoma.
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The aims of this study were: (1) to evaluate the ability of
selected phenylpiperazine derivatives to compete with MIBG
uptake by cultured neuroblastoma cells; (2) to evaluate the
uptake and retention of a model phenylpiperazine, namely, 4-
(3-['251]iodophenyl) piperazine, in cultured neuroblastoma
cells; and (3) to compare the biodistribution of 4-(3-
['25I]iodophenyl) piperazine with [1251]MIBG in rats.
Materials and methods
Materials
All reagents were obtained as the highest available grade
from commercial sources. 4-(3-chlorophenyl)-piperazine
(mCPP), 4-phenylpiperazine (PP), 4-(3-trifluoro methyl
phenyl)-piperazine (TFMPP) (1,1-dimethyl-4-phenyl)-pipera-
zinium hydrochloride (DMPP) and the piperidine derivative
chlorophenyl hydroxypiperidine (CP(OH)P), desmethylimi-
pramine (DMI) and serotonin (5HT) were obtained from
Sigma Chemical Co. 1-Carboxamidino-4-phenylpiperazine
(CAPP) was prepared according to previously described
methods (Hanson, 1982). Structures of the ligands used in
this study are shown in Figure 1.
Synthesis of 1-carboxamidino-4-phenyl-piperazine (CAPP)
4-Phenyl-piperazine hydrochloride (2.00 g), triethylamine
(2.50 g) and methylthiopseudourea sulphate (1.50 g) were
added to a round bottom flask and the solution was refluxed
at 100°C for 6 h using an oil bath. The reaction mixture was
then cooled to room temperature and transferred to an ice
bath. On cooling the product crystallised. The precipitate was
filtered, washed twice with ice-cold water, transferred to a
clean preweighed round bottom flask and dried under
vacuum overnight. The yield of dry product was 0.54 g.
The product was dissolved in 30 ml of 2N HCl and excess
HCl was removed by rotary evaporation. The resulting salt
was dried under vacuum overnight. The yield offinal product
was 0.42 g (- 17%). The product was characterised by silica
gel thin layer chromatography developed with ethanol-ethyl
acetate-ammonium hydroxide, 20:20:1, melting point and 'H
NMR [Varian model 300XL (300 MHz)].
N NH
4-Phenyl-piperazine
N NH
CF3
4-(3-Trifluoromethyl phenyl)-piperazine
N NH
CI
4-(3-Chlorophenyl)-piperazine
Synthesis and radiolabelling of MIBG
MIBG was prepared according to the methods of Wieland et
al. (1980). ['251I]MIBG was prepared by a modification of the
procedure reported by Mangner et al. (1982). Radiochemical
purity was determined before experimental use. Only
preparations with purities of greater than 95% were used.
Typically, the specific activity of the radiopharmaceutical was
approximately 5 mCi mg-'.
Radioiodination of4-(3-chloro-phenyl)-piperazine (mCPP)
[1251] labelled 4-(3-iodo-phenyl)-piperazine(IPP) was prepared
using the solid phase halogen exchange reaction described by
Manger et al. (1982) and later applied to iodo- for chloro-
substitution (Gildersleeve, et al., 1989). One milligram of
mCPP in 0.3 ml of water was added to a sterile glass vial
followed by 0.3 ml ofa 0.1 M ammoniumsulphate solution. To
thismixture was added ['251I]NaI (Amersham International) in a
volume of 20-50 Ml of dilute sodium hydroxide. The vial was
sealed with a Teflon/silicone septa and aluminium crimp top,
vented with a 20-gauge butterfly needle attached to a 20 ml
syringe and placed in a dry heating block at 175°C for 1 h. The
dry mixture was initially reconstituted with 1 ml of distilled
water and the efficiency of radioiodine incorporation was
assayed by TLC using TLC-SG (Merck) as stationary phase
and ethanol-ethyl acetate-ammonium hydroxide (20:20:1) as
mobile phase. In this system IPP is retained at the origin
(Rf=0.0) and I- migrates with Rf=0.8. Radioiodine
incorporation was approximately 78%. Removal ofunreacted
radioiodine was accomplished by anion exchange chromato-
graphy (Ott et al., 1992). Briefly, the reaction product was
dissolved in 0.5 M acetate buffer (pH 5) and passed through a
sterile anion exchange membrane (AG1-X8, BioRad) in the
carbonate form. The final product was passed through a
Millex-GS 0.22 ,um filter (Millipore Corp.). The radiochemical
purity ofthe final product was >95%.
Cell culture
The human neuroblastoma cell line SK-N-SH was obtained
from the American Type Culture Collection (ATCC,
N N/CH3
\=/ / ~~~~CH3
*HCI
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Figure 1 Structures of phenyl piperazine ligands used in this study.Phenylpiperazines for targedng neuroblastoma
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Figure 2 The effect of increasing concentration of phenylpiper-
azine ligands on the uptake of MIBG by SK-N-BE(2C) cells. The
order of affinity for inhibition of MIBG uptake was
IPP- >CAPP CPP>DMPP>CP(OH)P>TFMPP. The standard
error of the mean for each data point was A 10%.
Bethesda, MD, USA). The human neuroblastoma cell line
SK-N-BE(2C) was kindly provided as a gift from Dr J
Beidler. The cell lines were grown in T125 Nunc flasks
containing Eagle's medium, 10% fetal calf serum (FCS) and
20 mM Hepes buffer (pH 7.3). These cell lines have previously
been shown to be of neuroendothelial origin and to have
characteristic neuroblastoma-like morphology and histochem-
istry (Biedler et al., 1990). Bulk quantities of cells were grown
in Falcon tissue culture flasks (75 cm2) in a 5% carbon
dioxide/air atmosphere in a humidified water jacketed
incubator at 37°C. The culture medium was minimal
essential medium (MEM) supplemented with glutamine,
Earl's salts, sodium pyruvate, penicillin, streptomycin, Hepes
(10 mM) and fetal bovine serum (10%), pH 7.4.
For the experiments described below, cells were harvested
using trypsine/versine (Sigma Chemical Co.) and plated into
multiwell tissue culture plates (24 deep well, flat bottom,
tissue culture-treated polystyrene plates, Falcon) at a
concentration of approximately 5 x I05 cells per well. The
cells were grown to near confluence in the medium described
above. In most cases, experiments were performed 24 h after
plating. Whenever possible experiments were performed with
both cell lines.
Ten minutes before use of the cells, the medium was
changed to Eagle's salt solution containing 20 mM Hepes
without FCS (Eagle's/Hepes). The medium was heated to
37°C before use. Ligand and [1251]MIBG were allowed to
incubate in the presence of the cells as described below. After
the appropriate incubation period the medium was removed
and the cells were then rinsed with 1 ml of ice-cold Eagle's/
Hepes to remove non-specifically bound MIBG. The cells
were harvested using trypsine/versine. Initial incubation
medium, wash and cell pellet were counted for radioactivity
using a well-type gamma counter (MR80 Kontron, UK or
LKB model no. 1282, Wallac Oy, Finland) set to the [1251]
gamma energy. Cell number was determined with a
haemocytometer. All experiments were performed in tripli-
cate.
Competitive inhibition of MIBG uptake by phenylpiperazines
The ability of selected phenylpiperazines to inhibit MIBG
uptake by the neuroblastoma cell line SK-N-BE(2C) was
determined by incubating the cells with [125I]MIBG (0.1 MUM)
for 2 h in the presence of varying concentrations of test
ligand. In previous studies it has been shown that MIBG
uptake apparently reaches 90% of maximum within 2 h.
Determination of the percentage binding of MIBG to cells in
the presence of competing ligand was determined by
expressing cell-associated MIBG radioactivity as a percen-
tage of total radioactivity. These values were compared with
the percentage MIBG uptake in the absence of competing
ligand (control). All values were normalised to the average
number of cells. The concentration of competing ligand
which inhibited MIBG binding by 50% of the control value
(IC50) was determined by graphical analysis.
Uptake and retention of [125I]IPP by neuroblastoma cells
The potential of phenylpiperazines as targeting agents for
neuroblastoma is suggested by the ability ofthese compounds
to inhibit the uptake of [1251]MIBG in vitro. In order to
understand better the potential of these compounds for
targeting neuroblastoma it was necessary to characterise the
uptake and retention behaviour of a model phenylpiperazine.
4-(3-['251]iodophenyl)-piperazine was chosen for evaluation on
the basis of the in vitro competition studies (see below) which
indicated that 4-(phenyl)-piperazine and the chloro analogue,
CPP, were more effective than CAPP and other phenylpiper-
azines in inhibiting MIBG uptake.
The uptake of ['25I]IPP by SK-N-SH and SK-N-BE(2C)
cells was studied as a function of time. For these studies, cells
were incubated in the presence of [1251I]IPP (0.1,IM) and
uptake was determined at various times. Retention was
studied by incubating the cells in the presence of [1251I]IPP
(0.1 uMm) for 2 h, followed by removal of the ['25I]IPP
containing medium and replacement with fresh medium (no
[1251]IPP) and determination of cell bound radioactivity at
various times.
Studies of the selectivity of [1251I]IPP uptake and
characterisation of the transport system involved were also
performed. For these studies, cells were co-incubated in the
presence of 0.1 ,uM [1251]IPP and one of the following
compounds: MIBG, DMI, 5HT, TFMPP, CPP and IPP in
order to determine the ability of these agents to inhibit
[1251I]IPP uptake. The phenylpiperazines with greatest affinity
for the transporter should be preferred ligands for further
development. The degree of inhibition by MIBG should
indicate if the transporter is similar to that responsible for
MIBG uptake. Since phenylpiperazines are known to interact
with serotonin (5HT) receptor sites, 5HT was studied as a
competitive inhibitor of [1251I]IPP uptake. The well-known
Uptake-I inhibitor, desmethylimipramine (DMI), was also
studied.
Biodistributions of [125I]IPP and ['25I]MIBG in normal rats
The biodistributions of [1251]4-(3-iodophenyl)-piperazine
([1251]IPP) and [125I]MIBG were measured in separate groups
of animals. Determination of the distribution of [1251I]IPP in
normal animals will give an indication of expected target to
normal tissue ratios compared with MIBG. This data, in
conjunction with the results of the in vitro experiments,
should establish the feasibility of using phenylpiperazines for
imaging neuroblastoma.
Biodistribution studies were performed in groups of thirty
normal male Sprague-Dawley rats weighing approximately
150 g (Charles River Breeding Laboratories, Burlington, MA,
USA). The animals were injected intravenously (via tail vein)
with approximately 5 yCi (185 kBq) of each tracer to
determine biodistribution at 5, 30, 60, 120 and 1440 min
(each compound was evaluated in six animals at each time
point). Samples of blood, heart, lung, liver, spleen, kidney,
adrenal, stomach, gastrointestinal tract, testes, skeletal
muscle, bone and brain were weighed and radioactivity was
measured with a well-type gamma counter (LKB model no.
1282, Wallac Oy, Finland). To correct for radioactive decay,
aliquots of the injected doses were counted simultaneously.
The results were expressed as percentage injected dose per
gram and percentage injected dose per organ as well as targetPhenylpiperazines for targeting neuroblastoma
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to background ratios (defined as percentage injected dose per
gram adrenal/percentage injected dose per gram normal
tissue).
Statistical methods
The results of the biodistribution studies were evaluated by
analyses of variance (ANOVA) with a linear model in which
compound and time were the classification variables:
%ID g- or %ID per organ=Compound+Time+ Com-
pound*Time. Post hoc comparisons were performed by
Duncan's new multiple range test (Duncan 1955). The first
subscript ofeach F value is the number ofdegrees offreedom
for: the first classification variable (n- 1), the second
classification variable (mr-1) or the interaction [(n-1) x
(mi-1)]. The second subscript is the number of residual
degrees of freedom (total number of observations, n x m). All
results are expressed as mean+the standard error of the
mean (s.e.m.).
Results
Synthesis of CAPP
CAPP was prepared by the method of Hanson (1982). Silica
gel thin-layer chromatography (TLC-sg) showed the presence
of a single UV absorbing band with an Rf of 0.05. Proton
NMR was in agreement with literature values.
Radiolabelling of iodophenyl piperazine ([I251]IPP)
Radioiodine incorporation into chlorophenyl-piperazine was
>75% as determined byTLC-sgusingethanol-ethyl acetate-
20% ammoniumhydroxide(20:20:1) asmobilephase. Removal
of unreacted radioiodine was accomplished by passing the
reaction mixture through an anion exchange resin membrane
(BioRad AGI-X8). After purification, radiochemical purity
was always greater than 95% as determined by radio-TLC. In
this system the Rfofradioiodinated phenylpiperazine was 0.05,
and I- migrates with Rf=0.8.
Radiolabelling of Metaiodobenzylguanidine (MIBG)
The radiochemical purity of ['25I]MIBG was always greater
than 95% as determined by TLC-sg (Merck) as stationary
phase and ethanol-ethyl acetate -ammonium hydroxide
(20:20:1) as mobile phase. In this system MIBG stays at the
origin (Rf=0.05) and I- migrates with Rf=0.8.
cells was studied after a 2 h incubation followed by removal
of the medium containing [1251]IPP and replacement with
fresh medium without [1251I]IPP. After an early rapid washout
of - 50% of the initial radioactivity, retention remained
constant up to 3 h (data not shown). The uptake and
retention of ['25I]IPP is similar to the behaviour of MIBG
over the same time interval (Babich, 1994).
The ability of the halogenated phenylpiperazines to inhibit
['25I]IPP uptake into both neuroblastoma cell lines was
evaluated with increasing concentrations of ligand. IPP self-
inhibited [1251]IPP at approximately 10 fold lower concentra-
tion than MIBG in both cell lines. These data indicate that
IPP has a relatively high affinity for these cell lines with
approximate IC50s of 3 ltM, a concentration similar to that
required for inhibition of ['251]MIBG (2.5 gM) uptake. The
significance of the higher concentration of MIBG required to
inhibit [125I]IPP uptake is unclear since MIBG self-inhibits at
a concentration of approximately 0.4 ,UM. However, the
observed difference may be due to more rapid association
of IPP with the transporter rather than a thermodynamic
effect. A prolonged incubation period may clarify these
differences in apparent affinity.
Serotonin produced only a slight reduction in uptake at
the highest concentrations studied. Although not statistically
significant, this effect appeared to be slightly more
pronounced in SK-N-BE(2C) cells. In contrast, DMI was a
potent inhibitor of [1251I]IPP uptake in both cell lines. This
strongly suggests that [125I]IPP uptake is mediated via the
uptake-I transporter. The IC50s of DMI were 1.5 gLM and
0.6,M for SK-N-BE(2C) and SK-N-SH respectively. The
IC50s of 5HT were > 100 Mm in both cell lines.
In order to characterise the structural preferences of the
transporter which is responsible for [251I]IPP uptake, the
abilities of TFMPP, CPP and IPP to inhibit [1251]IPP uptake
Table I IC50s for competitive inhibtion of [1251]MBG uptake by
neuroblastoma cell line SK-N-BE(2C) of phenylpiperazines
Compound IC50 (MM)
DMPP 5
pp 1.5
CPP 2.5
CAPP 2.5
CP(OH)P 30
TFMPP 65
MIBG 0.3
Competitive binding with ['25I]MIBG
Figure 2 shows the effect of increasing concentrations of
phenylpiperazine ligands on the uptake of MIBG into SK-N-
BE(2C) cells. The concentrations of each ligand required to
produce a 50% inhibition of MIBG uptake are summarised
in Table I. IPP, CAPP and mCPP had similar IC50 values,
within an order of magnitude of MIBG itself. DMPP was
slightly less potent than CAPP and mCPP. CP(OH)P and
TFMPP had potencies which were approximately 100- and
200-fold lower than the other phenylpiperazines studied.
Hence, the order of potency for inhibition of MIBG
uptake was PP > CPP = CAPP > DMPP > CP(OH)P >
TFMPP (P<0.05).
In vitro evaluation of[I251]3-iodophenylpiperazine in
neuroblastoma
The uptake of ['25I]IPP into the neuroblastoma cell lines, SK-
N-BE(2C) and SK-N-SH, was studied as a function of time
using a fixed concentration of IPP (0.1 gM). The uptake
kinetics of[1251]IPP are shown in Figure 3. The rate ofuptake
was similar in both cell lines and was greatest over the time
period 0 to 60 min. After 60 min the rate decreased.
The retention of [1251]IPP by SK-N-SH and SK-N-BE(2C)
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Figure 3 Uptake of [1251]3-iodophenylpiperazine by neuroblas-
tomas cells in culture. Cells (106 per well) were incubated in the
presence of 0.1 M [125I]IPP for various time intervals. Error bars
smaller than the symbols are not shown.
10 -
r-were studied. In both cell lines, IPP was the most potent
inhibitor of ['25I]IPP uptake, followed by mCPP and
TFMPP. This finding supports the choice of ['25I]IPP as
Table II Biodistribution of [1251]IPP and [1251]MIBG in the rat
Organ Time (min) IPP MIBG
Blood 5
Heart
Lung
Liver
Spleen
Kidney
Adrenal
Stomach
30
60
120
1440
5
30
60
120
1440
5
30
60
120
1440
5
30
60
120
1440
S
30
60
120
1440
5
30
60
120
1440
S
30
60
120
1440
5
30
60
120
1440
0.16+0.012
0.28+0.004
0.30+0.026
0.25+0.013
0.03 +0.002
1.31 +0.058
0.46+0.017
0.44+0.041
0.21 +0.006
0.03+0.002
9.41 +0.355
3.38+0.246
2.45+0.134
0.79+0.037
0.05+0.003
1.13+0.072
1.52+0.069
1.56+0.059
1.14+0.029
0.33+0.007
0.10+0.096
0.75+0.026
0.60+0.031
0.25+0.010
0.03 +0.001
1.25 +0.057
0.94+0.036
1.11 +0.055
0.74+0.027
0.11 +0.009
1.58 +0.081
1.01 +0.077
1.21 +0.071
0.40+0.025
0.08+0.005
0.45+0.027
0.10+0.059
1.71 +0.101
2.11 +0.126
0.15+0.012
0.13+0.010
0.10+0.002
0.12+0.000
0.10+0.000
0.02+0.001
2.96+0.237
1.94+0.082
1.68 +0.109
1.18 +0.066
0.09+0.004
3.79+0.196
2.08+0.078
1.66+0.122
0.95+0.029
0.09+0.007
0.95+0.073
0.70+0.032
0.43+0.021
0.34+0.016
0.04+0.002
0.89+0.084
0.70+0.032
0.58+0.041
0.61 +0.037
0.07+0.006
1.10+0.140
0.48 +0.019
0.41 +0.025
0.35 +0.027
0.05+0.003
1.30+0.168
1.17+0.039
1.03 +0.029
1.33 +0.092
0.79+0.070
0.31 +0.029
0.23 +0.030
0.60+0.035
0.68 +0.087
0.19+0.021
GI tract 5 0.41 +0.019 0.36+0.078
30 0.62+0.035 0.59+0.020
60 0.65 +0.044 0.58+0.030
120 0.75+0.074 0.61+0.024
1440 0.05+0.004 0.09+0.006
Testes 5 0.24+0.015 0.13+0.006
30 0.38+0.016 0.18+0.006
60 0.36+0.007 0.14+0.004
120 0.29+0.008 0.15+0.009
1440 0.01 +0.001 0.03+0.003
Muscle 5 0.44+0.019 0.28+0.027
30 0.23+0.014 0.34+0.022
60 0.18+0.014 0.33+0.022
120 0.12+0.005 0.36+0.026
1440 0.01 +0.005 0.04+0.004
Bone 5 0.38+0.021 0.32+0.015
30 0.30+0.015 0.34+0.021
60 0.26+0.013 0.24+0.010
120 0.15+0.020 0.27+0.020
1440 0.01 +0.009 0.02+0.003
Brain 5 0.84+0.035 0.05+0.005
30 0.85+0.051 0.03+0.002
60 0.68+0.036 0.03+0.002
120 0.32+0.010 0.02+0.002
1440 0.01 +0.001 0.004+0.000
Percentage injected doses per g (mean+s.e.m.).
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an initial radiolabelled tracer for the study of this class of
compounds and reflects the previous finding that TFMPP
has a significantly lower ability to inhibit MIBG uptake
compared with mCPP or IPP. The IC5ss for IPP, CPP and
TFMPP were 2.5, 7.0 and >20 giM for SK-N-BE(2C) and
1.8, 9.0 and 40 gM for SK-N-SH respectively. The IC50s for
MIBG were 18 and 25,M for SK-N-BE(2C) and SK-N-SH
respectively.
Biodistributions of[I251]IPP and [12'I]MIBG in normal rats
Based on the in vitro results, the biodistributions of [251I]IPP
and ['251]MIBG were compared in normal rats. The results of
these studies are summarised in Table II. With the exceptions
of kidney, stomach and the gastrointestinal tract, the tissue
concentrations of both compounds decreased with time.
In blood, ANOVA demonstrated significant main effects of
compound (F1,56=83.48, P<0.0001) and time (F4,56=29.23,
P<0.0001). However, compound by time interactions were not
significant. The order of concentrations of the compounds in
blood was IPP>MIBG. In cardiac tissue, ANOVA showed
significant main effects of compound (F1,52=143.15,
P<0.0001), and time (F4,52=46.21, P<0.0001), and com-
pound by time interaction (Fg,64= 3.69, P< 0.001). The order of
concentrations of the compounds was MIBG>IPP. In lung,
ANOVA demonstrated significant main effects of compound
(F1,50=21.29, P<0.0001) and time (F450=45.50, P<0.0001),
and compound by time interaction (F9,65 = 13.80, P<0.0001).
The order of concentrations of the compounds was
IPP>MIBG (P<0.01). In liver, ANOVA showed significant
main effects ofcompound (F1,53= 137.46, P<0.0001) and time
(F4,53 = 37.88, P<0.0001), however compound by time interac-
tion was not significant. As in lung, the order ofconcentrations
of the compounds was IPP>MIBG. In spleen, ANOVA
demonstrated a significant main effect of time (F5,42=71.87,
P<0.0001). In this organ, themain effect ofcompound was not
significant (F1,52=2.41). In kidney, ANOVA showed significant
main effects of compound (F1,54=61.99, P<0.0001) and time
(F4,54=60.63, P<0.0001), and compound by time interaction
(F9,69= 10.94, P<0.0001). The order of concentrations of the
compounds was IPP>MIBG. In adrenal, ANOVA demon-
strated significant main effects of compound (F1,49=12.45,
P<0.001) and time (F4,49= 16.54, P<0.0001), and compound
by time interaction (Fg,53=5.56, P<0.0001). The order of
concentrations of the compounds was MIBG>IPP. In
stomach, ANOVA demonstrated significant main effects of
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Figure 4 Uptake of [1251]IPP and [1251]MIBG by the adrenal
gland of normal rats. These data demonstrate the similar levels of
early uptake for both tracers with greater washout of IPP at later
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compound (F1,45=51.75, P<0.0001) and time (F4,45=24.90,
P<0.0001), and compound by time interaction (Fg,53= 5.56,
P<0.0001). The orderofconcentrations ofthecompounds was
IPP>MIBG. In the gastrointestinal tract, ANOVA demon-
strated significant main effects of time (F4,52=62.88,
P<0.0001), but showed no significant effect of compound
(F1,52=3.927). In testis, ANOVA demonstrated significant
main effects of compound (F1,50=94.75, P<0.0001) and time
(F4,50=49.58, P<0.0001), and compound by time interaction
(Fg,67=4.77, P<0.001). The order of concentrations of the
compounds was IPP>MIBG. In skeletal muscle, ANOVA
showed significant main effects of compounds (F1,47= 10.38,
P<0.01) and time (F4,47=22.97, P<0.0001), however com-
pound by time interaction was not significant. The order of
concentrations of the compounds was MIBG>IPP. In bone,
ANOVA demonstrated a significant main effect of time
(F4,48 =80.42, P<0.0001) but demonstrated no significant
main effect of compound (F1,48=0.002). In brain, ANOVA
demonstrated significant main effects of compound
(F1,51 = 123.56, P<0.0001), and time (F4,51 = 12.92, P<0.0001)
and compound by time interaction (F3,68=5.15, P<0.0001).
The order of concentrations of the compounds was
IPP>MIBG.
At the early time points, uptake of both compounds was
most prominent in the lung, heart and adrenals. Although
maximal adrenal uptake ofIPP was greater or equal to that of
MIBG from 5 to 60 min after injection, by 2 h the
concentration of [125I]3-iodophenyl-piperazine dropped to
Blood Heart
10
.. . . . . .9 9* s9 |s
500 1000 1500
Time (min)
Lung
1500
Time (min)
0.1
0 500 1000
Time (min)
1500
Liver
100 _
10
0
01
0.1
0 500 1000 1500
Time (min)
Spleen Kidney
0 500 1000 1500 0 500 1000
Time (min) Time (min)
1500
Figure 5 Selected target to background ratios for IPP (-O-) and MIBG (....0....) (defined as % injected dose per gram adrenal/%
injected dose per gram other tissue).
lUU
0
._
4 -
(a
In
0
0)
.+-_
0)
c
0
Cu
H-
10l
0
10
0
._
e)
U,
U.
m
cu
4-
0)
c0
0.1
100
0 500 1000
0
4-
a)
Cl, en
._a
E
0
0
0) n
Cu
10
1 Ato _
1
1
IPhenY%iper Ms for targeting nexwoblastona
JW Babich et al
923
approximately 0.40 o per g. while MIBG remained at
approximately 1.3%/6 per g (Figure 4). The differences
increased even further in favour of MIBG by 24 h after
injection. The target-background (T B) ratios for IPP
increased with time in lung. spleen and heart. In blood and
kidney the T B ratios decreased with time. In contrast. T B
ratios for MIBG increased with time in most tissues (Figure 5).
Discu%ion
In the present study we have demonstrated that it is possible
to use an inhibition assay to screen for compounds which
display affinity for neuroblastoma in a manner mechan-
istically similar to MIBG. Our results demonstrate that
selected phenylpiperazines demonstrated good inhibition of
[1'5]MIBG uptake by neuroblastoma cells. Of the phenylpi-
perazines studied. ['251]IPP was also shown to accumulate in
neuroblastoma. Our data support the concept that ['2I1IPP is
taken up by a specific transporter which is saturable and that
this uptake is strongly inhibited by the known uptake-1
inhibitor. DMI.
As phenylpiperazines are known to interact with 5-HT
receptors. competition of ["51]IPP with 5HT was also used to
characterise uptake. The weak inhibition of uptake by 5HT
indicates that the transporter responsible for IPP uptake is
more specific for IPP than 5HT. Further work is needed to
characterise IPP and its mode of uptake fully. as it has been
reported that certain serotonin receptors are present on some
neuroblastoma cell lines (Hoyer et al., 1988; Watling, 1988).
but not serotonin uptake transporters (Pranzatelli and Balletti.
1992). The strong inhibition of IPP uptake by DMI suggests
such receptors may play only a minor role. if any.
As described above, at early times after injection. the
distribution of IPP is not only similar to MIBG but of the
same magnitude in tissues such as the heart. lung and
adrenals. Although adrenal uptake of [125I]IPP initially
exceeded that of MIBG. its relatively rapid washout suggests
that retention mechanisms may dominate at late time points.
Differences in retention may be due to the effective charges
associated With the secondarv amine of IPP and the
guanidino group of MIBG. Also there may be stronger
binding of the guanidine moiety to intracellular targets such
as carboxylate groups of oxoanions (Muller et al.. 1988:
Wigley et al.. 1987).
The lack of stomach radioactivitv of ['51]IPP at later time
points indicates that radiolabelling at the meta position. via
iodine for chlonrne exchange. provides a more stable
radiopharmaceutical than direct iodimation of phenylpiper-
azines in which the amino group at the 4 position of the
piperazine ring directs labelling to the para position of the
phenyl nrng (Hanson et al.. 1986: Letiec et al.. 1986).
A potential drawback of IPP may be its significant
uptake in the brain as well as its accumulation in the lung.
Both organs would be particularly sensitive to high levels of
radiation in the case of therapy with this agent. The
accumulation of IPP in these organs may be reduced.
however. by derivatising the amino group at the 1 position
(as per CAPP). Changing this secondary amine to a
quarternary amine would hamper its ability to cross the
bloodd-brain barrier as would conversion to a carboxami-
dino group as demonstrated by the biodistribution data
reported by Hanson for the radioiodinated compound
(Hanson. 1982. 1985). A combination of iodination at the
3 position of the phenyl ring and alteration of the charge or
basicity of the amino group at the 1 position of the
piperazine ring. should provide a radiopharmaceutical With
improved radiochemical stability and lower brain and lung
uptake as well as similar in vivo characteristics to MIBG. In
addition. the phenylpiperazine compounds may allow for
further structural alterations and possible improvement over
MIBG.
Recently. the feasibility of producing an alpha-emitting
analogue of MIBG. r- 'AtJmeta-astatinatobenzyl guanidine
has been demonstrated (Vaidyanathan and Zalutsky. 1992).
The rationale for developing this agent is the greater
lethality of the alpha particle of '2"At as compared with
beta emissions of 131J. Although this compound is a good
first step towards an agent with greater radiotherapeutic
effectiveness. accumulation in normal organs will lead to
high radiation burden in normal tissues and will probably
limit its application. This is particularly true for the heart
where impaired function could result in significant
morbidity. In the present study we demonstrated that there
is significant uptake of [I'5]IPP by neuroblastoma in vitro
and decreased myocardial accumulation compared with
MIBG in vivo. As a carrier for _"At. phenylpiperazines
may offer reduced radiation burden to certain normal tissues
as compared with MIBG.
In summary, the potential of a new class of compounds
for targeting neuroblastoma has been demonstrated using
competitive inhibition studies. This approach appears to be
a reliable screening method for affinity for neuroblastoma
cells via uptake-1. Phenylpiperazines have been shown to
represent a class of compounds capable of inhibiting MIBG
uptake into neuroblastoma cells at the gM level. We
demonstrate here for the first time that specific radio-
iodinated phenylpiperazine analogues display significant
uptake into neuroblastoma cells which appears to be
saturable and inhibited by agents known to inhibit
uptake-1. The biological distribution of ['1`1]IPP is
significantly different from MIBG in a variety of tissues
and may represent a new avenue for exploitation in terms of
therapy and diagnosis.
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